ZIVO Bioscience Opens WellMetris Assay Development Lab at Notre Dame Innovation Center

KEEGO HARBOR, MI--(Marketwired - Sep 9, 2015) - ZIVO Bioscience, Inc. (OTCQB: ZIVO) announced today that it has opened an assay development lab for its WellMetris subsidiary in South Bend, IN at the Innovation Center located near the Notre Dame University campus. The lab co-locates assay development and instrument engineering in order to streamline the product development process and focus on future development initiatives.

"As we move toward product launch for our Gen One pre-clinical screening platform, we are simultaneously developing our smartphone-enabled health and nutrition platform, which borrows assays, instrumentation components and software from the Gen One platform," states Kerry Wilson, WellMetris Director of Engineering. "This strategy allows us to launch the personal health/nutrition platform on the heels of the Gen One launch. Further, as we expand into animal health with our bovine and canine tests, co-locating assay development and instrumentation engineering speeds up the iterative process of optimizing the assays with instrumentation and software."

WellMetris scientists are actively engaged in expanding the range of tests, targeting other biofluids such as saliva and serum to the platform, as well as the type of assays integrated into the test cartridges. Specifically, WellMetris principals are looking to protein or biologic-based assays that can be used with the Company's proprietary test cartridge and instrumentation platform.

"By expanding the biofluids tested and the type of assays used, we would be able to adapt our platform to a wider range of biomarkers," says Andrew Dahl, ZIVO Bioscience, Inc. CEO and manager of the WellMetris subsidiary. "It plays to our strengths and allows us to expand our product offerings. Further, we can anticipate that our Gen One human wellness test would be followed by an athletic conditioning test and a senior home-care metabolic test. As to animal applications, the WellMetris transition cow syndrome test has the potential to be another price-performance breakthrough. Our product development brief describes a test that can be performed in the dairy barn in 4 minutes or less for about $6, as compared to conventional tests that require a blood draw, overnight shipping and lab fees that quickly surpass $50 in total costs. By conducting the test on the dairy farm in a matter of minutes and keeping test costs low, producers would be able to more closely monitor the condition of cows transitioning through lactation and calving. If there's a problem, intervention in real time is possible."

About WellMetris, LLC

WellMetris, LLC is a wholly-owned subsidiary of ZIVO Bioscience, Inc. WellMetris develops proprietary health and wellness tests for humans and animals, basing its technology on the emerging science of metabolomics to identify, measure, analyze and report on various metabolic analytes.

About ZIVO Bioscience, Inc.

ZIVO Bioscience, Inc. (OTCQB: ZIVO) is a Michigan-based biotech company primarily engaged in the investigation of the health benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation.

About Innovation Center at Notre Dame

Innovation Park at Notre Dame connects innovators, market experts and capital providers to transform innovations into viable marketplace ventures. Located adjacent to the University of Notre Dame in South Bend, Indiana, the Park connects clients with key ingredients essential to commercial success. The 55,000 square-foot facility includes high-tech collaborative areas, fully equipped conference rooms, build-to-suit office suites and dry and wet laboratory space. The Park is designed to serve a variety of businesses, including ventures with expected commercial applications from core Notre Dame research areas as well as ventures that can benefit from access to expertise and resources available through the Park.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.